ClinicalTrials.gg
CompletedNCT03338803Updated May 6, 2019Results posted

Real World Glycemic Effectiveness of Linagliptin

An observational study in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2019-05-06.

Sponsored by Boehringer Ingelheim · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
11,001
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim — 2 open to participants now, 3 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Boehringer Ingelheim.

Enrollment
17th of 34
11,001 · median 10,286
Started
2017
with 3 others
Observational
34 of 130
none open now
Registered
106th of 130
by date

Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 17th largest by enrollment of the 34 observational ones that give a count, is one of 4 that started in 2017, is one of 34 observational ones, and was the 106th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, or all of them as a file.
02

Study summary

A non-interventional cohort study using existing data from patients in the Optum Clinical Database which contains electronic health record (EHR) data from providers across the United States to determine whether there is comparable effectiveness of linagliptin on glycemic effectiveness

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A non-interventional cohort study using existing data from patients in the Optum Clinical Database which contains electronic health record (EHR) data from providers across the United States to determine whether there is comparable effectiveness of linagliptin on glycemic effectivenes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 1 written prescription for linagliptin (Tradjenta®, Jentadueto®, or Jentadueto XR®)in the EHR (electronic health record) data during the identification period
  • ≥ 40 years of age based on the year of the index date
  • First active date in the EHR is ≥ 180 days prior to the index date
  • ≥ 1 diagnosis code representing Type 2 diabetes (T2DM) in the EHR data during the 180-day pre-index period or on the index date
  • ≥ 1 value during the 180-day pre-index period or on the index date
  • ≥ 1 HbA1c value 60 to 180 days after the index date

Exclusion criteria

Exclusion Criteria:

  • ≥ 1 written prescription, medication administration or medication history record for linagliptin or other dipeptidyl peptidase (DPP-4) inhibitor in the EHR data during the 180-day pre-index period
  • ≥ 1 written prescription or medication administration for a new antihyperglycemic medication other than linagliptin on the index date New antihyperglycemic medication will be defined as a written prescription or medication administration for any antihyperglycemic medication that was not present in the patient's written prescription, medication administration, or medication history records during the 180-day pre-index period.

Individual antihyperglycemic medications will be distinguished by generic name using the column labelled "Medication Name" in Tables 2 through 13. Combination products containing two generic ingredients will be considered as two distinct antihyperglycemic medications Note: This exclusion criterion is designed to exclude patients from the study sample if they start a new antihyperglycemic medication other than linagliptin on the index date. Patients that start a new antihyperglycemic medication in the follow-up period will not be removed from the study sample to avoid creating a biased sample. Addition of a new antihyperglycemic medication during follow-up will be evaluated through the sensitivity analysis described in Section 9.7.4.4. While we will be capturing additions of new therapies, discontinuation of linagliptin is not able to be accurately measured in electronic record data. The electronic record data capture prescriptions written by a prescriber, but it is not possible to know if patients received and adhered to their medication and there are no structured data fields to identify if and when a medication was discontinued by the patient or the provider

  • ≥ 1 diagnosis code or procedure code representing renal transplant, solid organ transplant, or bone marrow transplant in the EHR data during the 180-day pre-index period or on the index date
  • ≥ 1 diagnosis code representing in the EHR data during the 180-day preindex period or on the index date
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
11,001 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with a written prescription for linagliptin

    Drug: Linagliptin

Interventions

  • drug

    Also known as: ONDERO, TRAJENTA, TRAYENTA, TRAZENTA, TRADJENTA

06

What researchers measure

Primary outcomes

  1. Change in Glycosylated Hemoglobin (HbA1c) Across Age Categories

    Change in HbA1c among adults with type 2 diabetes mellitus (T2DM) within the 60 to 180 days following initiation of linagliptin across pre-defined age categories (40 to 54 years, 40 to 54 years, 65 to 74 years and 75+ years). Change in HbA1c, was calculated for each patient by subtracting the patient's last (most recent) HbA1c value during the pre-index period (including the index date) from the patient's last (most recent) HbA1c value 60 to 180 days after the index date.

    Time frame: Baseline and 60 to 180 days

  2. Change in Glycosylated Hemoglobin (HbA1c) Across Renal Function Categories

    Change in HbA1c among adults with type 2 diabetes mellitus (T2DM) within the 60 to 180 days following initiation of linagliptin across pre-defined renal function categories. Change in HbA1c, was calculated for each patient by subtracting the patient's last (most recent) HbA1c value during the pre-index period (including the index date) from the patient's last (most recent) HbA1c value 60 to 180 days after the index date. Renal function categories were presented based on patients with a pre-index estimated glomerular filtration rate (eGFR) value (eGFR\<30, eGFR 30 to 44, eGFR 45 to 59, eGFR 60 to 89, eGFR ≥ 90 milliliter/ minute/1.73 meter\^2 and eGFR not available).

    Time frame: Baseline and 60 to 180 days

Secondary outcomes

  1. Percentage of Adults With T2DM Who Achieve HbA1c < 7.0% Across the Pre-defined Age Categories

    Percentage of adults with T2DM who achieve HbA1c \< 7.0% within the 60 to 180 days following initiation of linagliptin across pre-defined age categories (40 to 54 years, 40 to 54 years, 65 to 74 years and 75+ years).

    Time frame: 60 to 180 days

  2. Percentage of Adults With T2DM Who Achieve HbA1c < 7.0% Across Renal Function Categories

    Percentage of adults with T2DM who achieve HbA1c \< 7.0% within the 60 to 180 days following initiation of linagliptin across pre-defined renal function categories. Renal function categories were presented based on patients with a pre-index estimated glomerular filtration rate (eGFR) value (eGFR\<30, eGFR 30 to 44, eGFR 45 to 59, eGFR 60 to 89, eGFR ≥ 90 milliliter/ minute /1.73 meter\^2 and eGFR not available).

    Time frame: 60 to 180 days

07

Results

Posted May 6, 2019

Participant flow

Non-interventional, retrospective cohort study using existing data from patients in the Optum Clinical Database which contains electronic health record (EHR) data for the period of 01 July 2011 through 31 March 2017.

Participant flow — Overall Study
MilestonePatients With Written Prescription for Initiating Linagliptin
Started11001
Completed11001
Not completed0

Outcome measures

PrimaryChange in Glycosylated Hemoglobin (HbA1c) Across Age Categories

Change in HbA1c among adults with type 2 diabetes mellitus (T2DM) within the 60 to 180 days following initiation of linagliptin across pre-defined age categories (40 to 54 years, 40 to 54 years, 65 to 74 years and 75+ years). Change in HbA1c, was calculated for each patient by subtracting the patient's last (most recent) HbA1c value during the pre-index period (including the index date) from the patient's last (most recent) HbA1c value 60 to 180 days after the index date.

Time frame:
Baseline and 60 to 180 days
Reported as:
Mean · Percentage (%)
Change in Glycosylated Hemoglobin (HbA1c) Across Age Categories
Percentage (%)Patients With Written Prescription for Initiating Linagliptin
Overall-0.51 ± 1.46
Age 40 to 54 years-0.65 ± 1.65
Age 55 to 64 years-0.59 ± 1.54
Age 65 to 74 years-0.43 ± 1.36
Age 75+ years-0.36 ± 1.21
PrimaryChange in Glycosylated Hemoglobin (HbA1c) Across Renal Function Categories

Change in HbA1c among adults with type 2 diabetes mellitus (T2DM) within the 60 to 180 days following initiation of linagliptin across pre-defined renal function categories. Change in HbA1c, was calculated for each patient by subtracting the patient's last (most recent) HbA1c value during the pre-index period (including the index date) from the patient's last (most recent) HbA1c value 60 to 180 days after the index date. Renal function categories were presented based on patients with a pre-index estimated glomerular filtration rate (eGFR) value (eGFR\<30, eGFR 30 to 44, eGFR 45 to 59, eGFR 60 to 89, eGFR ≥ 90 milliliter/ minute/1.73 meter\^2 and eGFR not available).

Time frame:
Baseline and 60 to 180 days
Reported as:
Mean · Percentage (%)
Change in Glycosylated Hemoglobin (HbA1c) Across Renal Function Categories
Percentage (%)Patients With Written Prescription for Initiating Linagliptin
Overall-0.51 ± 1.46
eGFR<30-0.22 ± 1.46
eGFR 30 to 44-0.33 ± 1.34
eGFR 45 to 59-0.47 ± 1.42
eGFR 60 to 89-0.55 ± 1.44
eGFR ≥ 90-0.70 ± 1.58
eGFR not available-0.45 ± 1.40
SecondaryPercentage of Adults With T2DM Who Achieve HbA1c < 7.0% Across the Pre-defined Age Categories

Percentage of adults with T2DM who achieve HbA1c \< 7.0% within the 60 to 180 days following initiation of linagliptin across pre-defined age categories (40 to 54 years, 40 to 54 years, 65 to 74 years and 75+ years).

Time frame:
60 to 180 days
Reported as:
Number · Percentage of patients (%)
Percentage of Adults With T2DM Who Achieve HbA1c < 7.0% Across the Pre-defined Age Categories
Percentage of patients (%)Patients With Written Prescription for Initiating Linagliptin
Overall35.72
Age 40 to 54 years30.28
Age 55 to 64 years35.59
Age 65 to 74 years37.89
Age 75+ years38.55
SecondaryPercentage of Adults With T2DM Who Achieve HbA1c < 7.0% Across Renal Function Categories

Percentage of adults with T2DM who achieve HbA1c \< 7.0% within the 60 to 180 days following initiation of linagliptin across pre-defined renal function categories. Renal function categories were presented based on patients with a pre-index estimated glomerular filtration rate (eGFR) value (eGFR\<30, eGFR 30 to 44, eGFR 45 to 59, eGFR 60 to 89, eGFR ≥ 90 milliliter/ minute /1.73 meter\^2 and eGFR not available).

Time frame:
60 to 180 days
Reported as:
Number · Percentage of patients (%)
Percentage of Adults With T2DM Who Achieve HbA1c < 7.0% Across Renal Function Categories
Percentage of patients (%)Patients With Written Prescription for Initiating Linagliptin
Overall35.72
eGFR<3046.69
eGFR 30 to 4438.88
eGFR 45 to 5940.19
eGFR 60 to 8935.75
eGFR ≥ 9030.12
eGFR not available30.37

Adverse events

Collected over Individual safety reporting is not applicable for this study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patients With Written Prescription for Initiating Linagliptin———

Baseline characteristics

Patients with a written prescription for linagliptin were identified during an identification period starting on 01 January 2012 and ending on 30 September 2016.

Age, Continuous
Age, Continuous(Years)Patients With Written Prescription for Initiating Linagliptin
Mean64.30 ± 11.37
Sex: Female, Male
Sex: Female, Male(Participants)Patients With Written Prescription for Initiating Linagliptin
Female5603
Male5398
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Patients With Written Prescription for Initiating Linagliptin
Hispanic or Latino927
Not Hispanic or Latino9550
Unknown or Not Reported524
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Patients With Written Prescription for Initiating Linagliptin
American Indian or Alaska Native0
Asian241
Native Hawaiian or Other Pacific Islander0
Black or African American1455
White8645
More than one race0
Unknown or Not Reported660
Estimated glomerular filtration rate (eGFR)
Estimated glomerular filtration rate (eGFR)(participants)Patients With Written Prescription for Initiating Linagliptin
<30679
30 to 441646
45 to 591727
60 to 893256
≥ 902603
eGFR not available1090
Age categories
Age categories(participants)Patients With Written Prescription for Initiating Linagliptin
40 to 54 years2325
55 to 64 years3332
65 to 74 years3077
75 years and above2267
08

Study locations

1 site
  • Optum
    Eden Prairie, Minnesota 55344, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Feb 2018, 2 months.

Results were first posted in May 2019, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2017
First posted
Nov 9, 2017
StartActual
Nov 21, 2017
Primary completionActual
Feb 2, 2018
CompletionActual
Feb 2, 2018
Results first posted
May 6, 2019
Last update
May 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03338803
Responsible party
Sponsor
First posted
Nov 9, 2017
Start date
Nov 21, 2017
Primary completion
Feb 2, 2018
Completion
Feb 2, 2018
Results posted
May 6, 2019
Last update
May 6, 2019
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion